Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jun;19(2):124-30.
doi: 10.4104/pcrj.2010.00008.

The feasibility of recruiting patients with early COPD to a pilot trial assessing the effects of a physical activity intervention

Affiliations
Randomized Controlled Trial

The feasibility of recruiting patients with early COPD to a pilot trial assessing the effects of a physical activity intervention

James Faulkner et al. Prim Care Respir J. 2010 Jun.

Abstract

Aim: To determine the feasibility of recruiting patients with early chronic obstructive pulmonary disease (COPD) to the Health Enhancing Activity in Lung THerapy (HEALTH) exercise and education programme.

Methods: Patients with early COPD were identified from general practices. Those meeting the study inclusion criteria were administered tiotropium throughout the study period. Participants were randomised to either an eight-week health enhancing and physical activity (HEPA) programme, or to a control group (usual care). Behavioural, physiological and psychosocial outcome measures were reported preand post-intervention.

Results: Out of 27 practices approached, 16 (59.3%) agreed to participate. Of 215 potentially eligible patients contacted, 60 (27.9%) replied. Twenty (33.3%) were randomised to either HEPA intervention (n=10) or usual care (n=10). Fourteen patients attended a postintervention assessment.

Conclusion: This study provides valuable information on the feasibility of conducting such a trial involving a physical activity intervention.

PubMed Disclaimer

Conflict of interest statement

In the last 3 years RJ has received speakers fees from Boehringer Ingelheim, Pfizer, GlaxoSmithKline, TEVA, Altana, Astra Zeneca, MSD, Tejin and Trinity Chiesi. RJ has sat on advisory boards related to COPD for Boehringer Ingelheim, Pfizer, GlaxoSmithKline, TEVA, Novartis, and Nutricia in the last 3 years and acted as a consultant to Pfizer and Boehringer Ingelheim. No other author has any conflict of interest.

Similar articles

Cited by

Publication types